Cargando…

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer

Cancer cells can be selectively targeted by identifying and developing antibodies to specific antigens present on the cancer cell surface. Cytotoxic agents can be conjugated to these antibodies that bind to these cell surface antigens in order to significantly increase the therapeutic index of which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niaz, Muhammad O, Sun, Michael, Ramirez-Fort, Marigdalia K, Niaz, Muhammad J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105266/ https://www.ncbi.nlm.nih.gov/pubmed/32257692 http://dx.doi.org/10.7759/cureus.7147

Ejemplares similares

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Metastatic Castrate-Resistant Prostate Cancer: A Rare Cause of Bowel Obstruction
por: Ehsanullah, Syed, et al.
Publicado: (2021)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Stauffer Syndrome as the Initial Presentation of Advanced Metastatic Prostate Cancer
por: Khanal, Sneha, et al.
Publicado: (2023)

Metastatic Prostate Cancer With Reticular Micronodular Opacities of Lung: A Case Report
por: Bojja, Srikaran, et al.
Publicado: (2023)

Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy
por: Findakly, Dawood, et al.
Publicado: (2022)

Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica
por: Condappa, Andrew, et al.
Publicado: (2018)

Evolving Natural History of Metastatic Prostate Cancer
por: Nafissi, Nellie N, et al.
Publicado: (2020)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Hemophagocytic Lymphohistiocytosis: A Rare Cause of Pyrexia of Unknown Origin
por: Khan, Salman, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Calderoni, Letizia, et al.
Publicado: (2023)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

A Case Report on Atypical Presentation of Metastatic Prostate Cancer
por: Lyonga Ngonge, Anthony, et al.
Publicado: (2022)

Disseminated Intravascular Coagulation as the Initial Presentation of Metastatic Prostate Adenocarcinoma
por: Greenberg, Daniel J
Publicado: (2021)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Mohammadzadeh, Mohammad, et al.
Publicado: (2018)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
por: Tagawa, Scott T., et al.
Publicado: (2013)

Metastatic Prostate Cancer Presenting as a Rectal Polyp: A Rare Occurrence
por: Uwagbale, Ese, et al.
Publicado: (2021)

Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
por: Brady-Nicholls, Renee, et al.
Publicado: (2021)

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
por: Chen, Jiaxian, et al.
Publicado: (2022)

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
por: Liu, Chang, et al.
Publicado: (2020)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Prostate Cancer Metastatic to the Peritoneum: A Road Less Traveled by a Common Malignancy
por: Tareen, Serene A, et al.
Publicado: (2019)

Effectiveness of Virchow’s Node Fine-Needle Biopsy for the Discovery of Occult Metastatic Prostate Cancer
por: Izquierdo Del Barco, Luciana, et al.
Publicado: (2022)

Pseudo-dense Hair Transplantation: Strategy of “Less Inside, More Outside” and Central Bulking with Curled Chest Hairs as Treatment for Scalp Scars
por: Feily, Amir, et al.
Publicado: (2020)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
por: Kessel, Katharina, et al.
Publicado: (2021)

Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts
por: Sartor, Oliver, et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Shifting Trends in Prostate Treatment: A Systematic Review Comparing Transurethral Resection of the Prostate and Holmium Laser Enucleation of the Prostate
por: Iqbal, Javed, et al.
Publicado: (2023)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Han, Sangwon, et al.
Publicado: (2021)

Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
por: Satapathy, Swayamjeet, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ss43ke1ok2qd01lvgcsk68ede